Friday, 29 October 2021

Australia's most trusted
source of pharma news

Friday, 29 October 2021

Moderna pips Pfizer... again

Posted 22 September 2021 PM

Another round of analysis of mRNA Covid jabs has found that when it comes to initial effectiveness Pfizer and Moderna vaccines are just about neck-and-neck but when measuring effectiveness over time, the gap widens with Moderna's Spikevax offering better results ahead of Pfizer's Comirnaty.

The new study published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report found from March to August 2021, the vaccine effectiveness against hospitalisation was 93 per cent for two doses of Moderna's vaccine and 88 per cent for two doses of Pfizer's jab.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read. If you don't have a password, just enter your email address and then click Login.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.